Depomed, Inc. (NASDAQ: DEPO)
According to the law firm press release, Depomed, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. Among other drugs, Depomed’s portfolio includes the opioids Nucynta (tapentadol) and Lazanda (fentanyl).